ESPR Stock Analysis: Buy, Sell, or Hold?
ESPR - Esperion Therapeutics, Inc.
$3.18
-0.01 (-0.31%)
âŧ
5d:
+0.63%
30d:
+1.27%
90d:
+45.87%
WAIT
LOW Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When ESPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ESPR is fairly priced but lacks strong directional signals. At -34.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ESPR is fairly priced but lacks strong directional signals. At -34.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.23
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.35
49.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ESPR is currently trading at $3.18, which is considered fair based on recent price action. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.9) compared to its historical average (38.6). Remarkably, the market is currently pricing in an annual earnings decline of 34.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ESPR is in a strong uptrend. The price is currently testing key support at $3.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ESPR is in a strong uptrend. The price is currently testing key support at $3.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
53/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
62.9%
Protect Your Profits
Holding ESPR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- NEUTRAL: Near Wall St target ($3.19)
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$3.15
Resistance Level
$3.19
Current Trend
Strong Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.89
Wall Street Target
$3.19
(+0.3%)
Revenue Growth (YoY)
23.2%
Profit Margin
-1.8%
Valuation Discount vs History
-34.4% cheaper
PE vs Historical
10.9 vs 38.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-34.4%
(market-implied from PE analysis)
1-Year Target
$2.86
(-10%)
2-Year Target
$2.58
(-19%)
3-Year Target
$2.32
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11â39)
$8.22
(+158%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.9 to 38.6
Stabilization Target:
$11.27
(+254.4%)
PE Expansion Potential:
+254.4%
Share & Embed Analysis
Last updated: August 23, 2026 5:48 AM ET
Data refreshes hourly during market hours. Next update: 6:48 AM
Data refreshes hourly during market hours. Next update: 6:48 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ESPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Halladay
SELL
6424 shares
2026-03-17
Benjamin Looker
SELL
5708 shares
2026-03-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$653 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced ESPR Option Strategies
Professional options setups generated by AI based on today's ESPR price and gamma walls.
